These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24285415)

  • 1. Synthesis of ximelagatran, melagatran, hydroxymelagatran, and ethylmelagatran in H-3 labeled form.
    Simonsson R; Stenhagen G; Ericsson C; Elmore CS
    J Labelled Comp Radiopharm; 2013 May; 56(6):334-7. PubMed ID: 24285415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs.
    Sjödin E; Fritsch H; Eriksson UG; Logren U; Nordgren A; Forsell P; Knutson L; Lennernäs H
    Drug Metab Dispos; 2008 Aug; 36(8):1519-28. PubMed ID: 18458048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
    Clement B; Lopian K
    Drug Metab Dispos; 2003 May; 31(5):645-51. PubMed ID: 12695354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model.
    Sjögren E; Bredberg U; Allard E; Arvidsson B; Bergquist J; Andersson TB; Lennernäs H
    Pharm Res; 2010 Apr; 27(4):597-607. PubMed ID: 20140637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ximelagatran in orthopaedic surgery.
    Eriksson B
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():10-7. PubMed ID: 15812199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers.
    Matsson EM; Eriksson UG; Knutson L; Hoffmann KJ; Logren U; Fridblom P; Petri N; Lennernäs H
    J Clin Pharmacol; 2011 May; 51(5):770-83. PubMed ID: 20663994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
    Hellgren M; Johansson S; Eriksson UG; Wåhlander K
    BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of tritium-labeled PF-622, a novel fatty acid amide hydrolase inhibitor.
    Zhang Y
    J Labelled Comp Radiopharm; 2017 Nov; 60(13):608-615. PubMed ID: 28869999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
    Eriksson UG; Dorani H; Karlsson J; Fritsch H; Hoffmann KJ; Olsson L; Sarich TC; Wall U; Schützer KM
    Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect on perfusion chamber thrombus size in patients with atrial fibrillation during anticoagulant treatment with oral direct thrombin inhibitors, AZD0837 or ximelagatran, or with vitamin K antagonists.
    Wolzt M; Eriksson UG; Gouya G; Leuchten N; Kapiotis S; Elg M; Schützer KM; Zetterstrand S; Holmberg M; Wåhlander K
    Thromb Res; 2012 Apr; 129(4):e83-91. PubMed ID: 21925716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and characterization of tritium labeled N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide.
    Hong Y; Hynes J; Tian Y; Balasubramanian B; Bonacorsi S
    J Labelled Comp Radiopharm; 2015 Aug; 58(10):414-8. PubMed ID: 26228905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor.
    Teng R; Sarich TC; Eriksson UG; Hamer JE; Gillette S; Schützer KM; Carlson GF; Kowey PR
    J Clin Pharmacol; 2004 Sep; 44(9):1063-71. PubMed ID: 15317834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol.
    Sarich TC; Johansson S; Schützer KM; Wall U; Kessler E; Teng R; Eriksson UG
    J Clin Pharmacol; 2004 Apr; 44(4):388-93. PubMed ID: 15051746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):245-53. PubMed ID: 16123911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of ximelagatran, melagatran and two intermediary metabolites in plasma by mixed-mode solid phase extraction and LC-MS/MS.
    Dunér K; Bäckström J; Magnell N; Svennberg H; Ahnoff M; Logren U
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):317-24. PubMed ID: 17296338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model.
    Edling Y; Sivertsson L; Andersson TB; Porsmyr-Palmertz M; Ingelman-Sundberg M
    Toxicol In Vitro; 2008 Sep; 22(6):1588-94. PubMed ID: 18640260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.